$238 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 36 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RLMD | New | RELMADA THERAPEUTICS INC | $9,102,000 | – | 404,000 | +100.0% | 3.83% | – |
| New | PYXIS ONCOLOGY INC SERIES B | $7,435,000 | – | 677,753 | +100.0% | 3.12% | – | |
| New | AVADEL PHARMACEUTICALS PLCsponsored adr | $4,686,000 | – | 580,000 | +100.0% | 1.97% | – | |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $3,186,000 | – | 230,000 | +100.0% | 1.34% | – |
| MRTX | New | MIRATI THERAPEUTICS | $2,934,000 | – | 20,000 | +100.0% | 1.23% | – |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $2,000,000 | – | 500,000 | +100.0% | 0.84% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $1,489,000 | – | 68,500 | +100.0% | 0.63% | – |
| MTEM | New | MOLECULAR TEMPLATES INC | $1,264,000 | – | 322,500 | +100.0% | 0.53% | – |
| GRTX | New | GALERA THERAPEUTICS INC | $1,205,000 | – | 262,500 | +100.0% | 0.51% | – |
| JNCE | New | JOUNCE THERAPEUTICS INC | $1,065,000 | – | 127,500 | +100.0% | 0.45% | – |
| NUVB | New | Nuvation Warrants*w exp 07/07/202 | $172,000 | – | 90,832 | +100.0% | 0.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.